{"id":"continue-with-triple-therapy","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL373625","moleculeType":"Small molecule"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Without specification of which three agents comprise this regimen, the mechanism cannot be precisely defined. Triple therapy regimens vary widely depending on the therapeutic area and clinical context—for example, in cardiovascular disease it may combine agents targeting different pathways, while in infectious disease it may use multiple antimicrobial agents with different mechanisms. The specific combination determines the overall therapeutic action.","oneSentence":"Triple therapy typically combines three complementary pharmacological agents to achieve synergistic therapeutic effects.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:31:01.296Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT07407140","phase":"PHASE3","title":"VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-04-30","conditions":"AML, Adult","enrollment":300},{"nctId":"NCT07491822","phase":"NA","title":"A Single-Arm, Single-Center, Phase II Clinical Study of Camrelizumab Combined With Radiochemotherapy as Neoadjuvant Therapy for Early-Stage Triple-Negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-03-25","conditions":"TNBC","enrollment":43},{"nctId":"NCT04677816","phase":"PHASE2","title":"Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2021-10-22","conditions":"Triple Negative Breast Cancer, Vitamin D Deficiency, Invasive Breast Cancer","enrollment":50},{"nctId":"NCT07484776","phase":"NA","title":"Metabolic Flexibility in Patients With Early Triple-negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Universidad Europea de Madrid","startDate":"2026-02-10","conditions":"Triple-Negative Breast Cancer (TNBC)","enrollment":40},{"nctId":"NCT04972136","phase":"NA","title":"rTMS for Depression in Young Adults With Autism","status":"RECRUITING","sponsor":"Centre for Addiction and Mental Health","startDate":"2021-01-14","conditions":"Autism Spectrum Disorder, Major Depressive Disorder","enrollment":80},{"nctId":"NCT07472868","phase":"PHASE3","title":"Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"J. W. A. Burger","startDate":"2026-03-03","conditions":"Locally Advanced Rectal Carcinoma","enrollment":394},{"nctId":"NCT05639556","phase":"","title":"Strength and Muscle Related Outcomes for Nutrition and Lung Function in CF","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jaeb Center for Health Research","startDate":"2023-04-20","conditions":"Cystic Fibrosis","enrollment":300},{"nctId":"NCT06134375","phase":"PHASE1, PHASE2","title":"A Study of Tetrathiomolybdate (TM) Plus Capecitabine","status":"RECRUITING","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2024-11-26","conditions":"Triple Negative Breast Cancer, Residual Disease","enrollment":204},{"nctId":"NCT03330847","phase":"PHASE2","title":"To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-03-07","conditions":"Metastatic Triple Negative Breast Cancer","enrollment":273},{"nctId":"NCT03178552","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2017-09-22","conditions":"Non-Small Cell Lung Cancer","enrollment":1000},{"nctId":"NCT06279130","phase":"PHASE2, PHASE3","title":"Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2024-01-29","conditions":"Resectable MMR-deficient Solid Tumors, Resectable MMR-proficient Solid Tumors","enrollment":133},{"nctId":"NCT03644667","phase":"PHASE2","title":"Tocilizumab in Cardiac Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-12-20","conditions":"Heart Transplant","enrollment":385},{"nctId":"NCT03808337","phase":"PHASE2","title":"Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2019-01-16","conditions":"Triple Negative Breast Cancer, Non Small Cell Lung Cancer, Metastatic Breast Cancer","enrollment":145},{"nctId":"NCT05650723","phase":"PHASE2","title":"Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2023-05-08","conditions":"Leukemia, Lymphocytic, Chronic, B-Cell","enrollment":50},{"nctId":"NCT03801369","phase":"PHASE2","title":"AMTEC IIT: Phase 2 Multiarm Study in TNBC","status":"TERMINATED","sponsor":"Gordon Mills, MD, PhD","startDate":"2018-12-12","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma","enrollment":24},{"nctId":"NCT06099769","phase":"PHASE2","title":"A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-10-18","conditions":"Metastatic Breast Cancer","enrollment":201},{"nctId":"NCT06976944","phase":"PHASE2","title":"Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer","status":"RECRUITING","sponsor":"Yukinori Ozaki","startDate":"2025-06-24","conditions":"Recurrent Triple-Negative Breast Cancer","enrollment":44},{"nctId":"NCT02264678","phase":"PHASE1, PHASE2","title":"Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2014-10-31","conditions":"Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer","enrollment":357},{"nctId":"NCT04683679","phase":"PHASE2","title":"A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-04-21","conditions":"Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Breast Cancer","enrollment":34},{"nctId":"NCT06384560","phase":"PHASE1, PHASE2","title":"Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5)","status":"RECRUITING","sponsor":"Amsterdam UMC, location VUmc","startDate":"2024-09-23","conditions":"Localized Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Adenocarcinoma","enrollment":66},{"nctId":"NCT06500884","phase":"PHASE2","title":"A Study to Evaluate Preventive Treatments for Talquetamab-related Oral Toxicity","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-08-26","conditions":"Relapse Multiple Myeloma, Refractory Multiple Myeloma","enrollment":130},{"nctId":"NCT07407920","phase":"PHASE2","title":"Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-10-09","conditions":"Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Early Stage HER2-Positive Breast Carcinoma","enrollment":120},{"nctId":"NCT05383196","phase":"PHASE1, PHASE2","title":"Onvansertib + Paclitaxel In TNBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Antonio Giordano, MD","startDate":"2022-09-30","conditions":"Breast Cancer, Invasive Breast Cancer, Unresectable Breast Carcinoma","enrollment":50},{"nctId":"NCT07231289","phase":"NA","title":"Effect of Soundscapes on Emotional Distress in Fibromyalgia: a 4×4 Crossover Trial","status":"COMPLETED","sponsor":"Universidad de Granada","startDate":"2025-11-24","conditions":"Fibromyalgia Syndrome","enrollment":72},{"nctId":"NCT04454437","phase":"PHASE2","title":"Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2020-10-23","conditions":"Metastatic Triple-negative Breast Cancer","enrollment":80},{"nctId":"NCT07378306","phase":"PHASE2","title":"FMD and Neoadjuvant Chemo-immunotherapy in TNBC","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02-01","conditions":"Breast Cancer","enrollment":80},{"nctId":"NCT07368543","phase":"PHASE2","title":"Sequencing SG vs. T-DXd in HER2-Low/TROP2-High Metastatic Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-01-16","conditions":"Metastatic Breast Cancer","enrollment":216},{"nctId":"NCT05455294","phase":"PHASE1","title":"Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jacqueline Garcia, MD","startDate":"2022-07-18","conditions":"Myeloid Malignancy, Myelodysplastic Syndromes, Myelofibrosis","enrollment":16},{"nctId":"NCT07346014","phase":"NA","title":"Sleep and Circadian Interventions for College Students at High Risk of Suicide","status":"NOT_YET_RECRUITING","sponsor":"University of Pittsburgh","startDate":"2026-03","conditions":"Sleep Disturbance, Sleep, Depression","enrollment":90},{"nctId":"NCT07371208","phase":"PHASE2","title":"Multicenter, Phase II Clinical Study of Sacituzumab Tirumotecan (Sac-TMT) in Combination With KL-A167 for Neoadjuvant Treatment of Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2025-12-24","conditions":"Breast Cancer","enrollment":40},{"nctId":"NCT06519370","phase":"PHASE3","title":"FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.","startDate":"2024-08-09","conditions":"Triple Negative Breast Cancer","enrollment":350},{"nctId":"NCT07351487","phase":"PHASE2","title":"Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07)","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2025-09-25","conditions":"TNBC - Triple-Negative Breast Cancer","enrollment":37},{"nctId":"NCT06682195","phase":"PHASE2","title":"Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2024-10-09","conditions":"TNBC, Triple Negative Breast Cancer","enrollment":35},{"nctId":"NCT07324473","phase":"PHASE2","title":"Ivarmacitinib Combined With Camrelizumab and Apatinib for Unresectable Advanced Hepatocellular Carcinoma With Acquired Resistance to Immune Checkpoint Therapy: A Single-Arm Exploratory Clinical Study","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Chongqing Medical University","startDate":"2026-01-01","conditions":"Hepatocellular Carcinomas, Resistance to Immunotherapy, Immunomodulation","enrollment":65},{"nctId":"NCT06162351","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Toxicities of PLX038, in Patients With Locally Advanced or Metastatic Triple-negative Breast Cancer","status":"TERMINATED","sponsor":"Institut Curie","startDate":"2024-04-17","conditions":"Breast, Cancer","enrollment":14},{"nctId":"NCT04986852","phase":"PHASE2","title":"Olinvacimab With Pembrolizumab in Patients With mTNBC","status":"TERMINATED","sponsor":"PharmAbcine","startDate":"2021-09-30","conditions":"Metastatic Triple-Negative Breast Cancer","enrollment":19},{"nctId":"NCT03997123","phase":"PHASE3","title":"Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2019-06-25","conditions":"Triple Negative Breast Neoplasms","enrollment":923},{"nctId":"NCT03013998","phase":"PHASE1, PHASE2","title":"Study of Biomarker-Based Treatment of Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Beat AML, LLC","startDate":"2016-11","conditions":"Previously Untreated Relapsed Refractory Acute Myeloid Leukemia","enrollment":3000},{"nctId":"NCT04510506","phase":"NA","title":"Artificial Pancreas - Adolescent Physiology & Psychology Longitudinal Evaluation","status":"COMPLETED","sponsor":"University of Virginia","startDate":"2020-11-19","conditions":"Type 1 Diabetes","enrollment":42},{"nctId":"NCT07110987","phase":"NA","title":"The Efficacy of Ursodeoxycholic Acid (UDCA) as Adjuvant Therapy to Phototherapy in the Management of Neonatal Indirect Hyperbilirubinemia","status":"RECRUITING","sponsor":"Tishreen University Hospital","startDate":"2025-06-26","conditions":"Hyperbilirubinemia, Neonatal Indirect","enrollment":70},{"nctId":"NCT05564650","phase":"PHASE1","title":"Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2023-01-12","conditions":"Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome, Refractory Myelodysplastic Syndrome","enrollment":6},{"nctId":"NCT06664801","phase":"PHASE2","title":"A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-11-14","conditions":"Pulmonary Arterial Hypertension","enrollment":164},{"nctId":"NCT06925750","phase":"PHASE2","title":"A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-05-12","conditions":"Pulmonary Arterial Hypertension","enrollment":130},{"nctId":"NCT05520723","phase":"PHASE2","title":"Preventive stRategy for IMMU132-relatED AEs in TNBC or Luminal Breast Cancer- PRIMED","status":"COMPLETED","sponsor":"MedSIR","startDate":"2023-02-06","conditions":"Triple Negative Breast Cancer, Breast Cancer, Advanced HR+/HER2- Breast Cancer","enrollment":50},{"nctId":"NCT05035407","phase":"PHASE1","title":"T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2022-03-08","conditions":"Kita-kyushu Lung Cancer Antigen 1, Human","enrollment":36},{"nctId":"NCT07259733","phase":"NA","title":"Rapid Management of Resistant Hypertension in the Public Health System (Fast Control)","status":"RECRUITING","sponsor":"Instituto Dante Pazzanese de Cardiologia","startDate":"2023-07-15","conditions":"Apparent Resistant Hypertension, Hypertension, High Blood Pressure","enrollment":142},{"nctId":"NCT04193059","phase":"PHASE3","title":"Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fudan University","startDate":"2019-12-20","conditions":"Breast Cancer","enrollment":1560},{"nctId":"NCT03449108","phase":"PHASE2","title":"LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-04-27","conditions":"Bone Sarcoma, Dedifferentiated Chondrosarcoma, Giant Cell Tumor of Bone","enrollment":30},{"nctId":"NCT07037134","phase":"NA","title":"Impact of Auditory Environments on Pain in Fibromyalgia: a 4×4 Crossover Trial","status":"COMPLETED","sponsor":"Universidad de Granada","startDate":"2025-08-04","conditions":"Fibromyalgia Syndrome","enrollment":88},{"nctId":"NCT05086393","phase":"PHASE4","title":"Duloxetine RCT on Postop TKA Outcomes","status":"COMPLETED","sponsor":"Rush University Medical Center","startDate":"2021-11-01","conditions":"Pain, Postoperative, Total Knee Arthroplasty","enrollment":241},{"nctId":"NCT03363893","phase":"PHASE1, PHASE2","title":"Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies","status":"COMPLETED","sponsor":"Carrick Therapeutics Limited","startDate":"2017-11-14","conditions":"Advanced Solid Malignancies","enrollment":124},{"nctId":"NCT03280563","phase":"PHASE1, PHASE2","title":"A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-12-22","conditions":"Breast Neoplasms","enrollment":144},{"nctId":"NCT03620643","phase":"PHASE2","title":"Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours","status":"COMPLETED","sponsor":"Royal Marsden NHS Foundation Trust","startDate":"2019-05-09","conditions":"Lobular Breast Carcinoma, Gastric Cancer, Triple Negative Breast Cancer","enrollment":33},{"nctId":"NCT07066189","phase":"NA","title":"Lifestyle, Exercise, And Nutrition (LEAN) Trial on Pathologic Complete Response in TNBC","status":"RECRUITING","sponsor":"Yale University","startDate":"2025-10-17","conditions":"Triple Negative Breast Cancer","enrollment":160},{"nctId":"NCT03564691","phase":"PHASE1","title":"Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-07-11","conditions":"Neoplasms","enrollment":470},{"nctId":"NCT04877821","phase":"PHASE2","title":"The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2021-09-15","conditions":"Triple Negative Breast Cancer","enrollment":31},{"nctId":"NCT07063095","phase":"PHASE3","title":"A Combination Therapy With Ceftazidime and Fosfomycin Will be Compared to Ceftazidime Alone in Hospitalized Adult Patients With Suspected Severe Gram-negative Bacterial Infections","status":"RECRUITING","sponsor":"Angela HUTTNER","startDate":"2025-08-25","conditions":"Gram Negative Infections, Sepsis and Septic Shock","enrollment":100},{"nctId":"NCT04846829","phase":"EARLY_PHASE1","title":"Effects of Intravenous (IV) Citalopram Hydrochloride During Transcranial Magnetic Stimulation in Major Depressive Disorder (MDD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, Los Angeles","startDate":"2017-04-24","conditions":"Major Depressive Disorder","enrollment":30},{"nctId":"NCT07182331","phase":"NA","title":"Brain Stimulation and Sensory Integration in Children With ASD","status":"ENROLLING_BY_INVITATION","sponsor":"Neurolab Plus","startDate":"2025-08-25","conditions":"Autism Spectrum Disorder (ASD)","enrollment":40},{"nctId":"NCT07178730","phase":"PHASE3","title":"NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"West German Study Group","startDate":"2026-01-31","conditions":"Breast Cancer, Triple-negative Breast Cancer","enrollment":765},{"nctId":"NCT04191616","phase":"PHASE2","title":"Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet","status":"COMPLETED","sponsor":"Amgen","startDate":"2020-08-06","conditions":"Relapsed or Refractory Multiple Myeloma","enrollment":54},{"nctId":"NCT07151586","phase":"PHASE2","title":"Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"UNICANCER","startDate":"2025-10","conditions":"Triple Negative Breast Neoplasms, Neoplasm Metastasis, HER 2 Low-expressing Breast Cancer","enrollment":260},{"nctId":"NCT06783868","phase":"","title":"Assessing the Neurological Outcomes After Atrial Fibrillation Ablation for Rhythm Control","status":"NOT_YET_RECRUITING","sponsor":"Kansas City Heart Rhythm Research Foundation","startDate":"2025-10","conditions":"Atrial Fibrillation, Stroke","enrollment":100},{"nctId":"NCT07139470","phase":"PHASE1, PHASE2","title":"Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-08-15","conditions":"Triple Negative Breast Cancer","enrollment":59},{"nctId":"NCT05582538","phase":"PHASE2","title":"Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel","status":"RECRUITING","sponsor":"IFOM ETS - The AIRC Institute of Molecular Oncology","startDate":"2022-12-15","conditions":"Triple Negative Breast Cancer Metastatic","enrollment":37},{"nctId":"NCT04434040","phase":"PHASE2","title":"Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2020-07-02","conditions":"Breast Cancer, Triple Negative Breast Cancer, Residual Cancer","enrollment":40},{"nctId":"NCT07124884","phase":"PHASE2","title":"5-fluorouracil Plus Panitumumab (Anti-EGFR) and Sotorasib (KRAS G12C Inhibitor) in First-line Treatment of Patients Non-eligible for a Doublet/Triplet Chemotherapy With Advanced Unresectab","status":"NOT_YET_RECRUITING","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2025-08-31","conditions":"Colorectal Carcinoma, KRAS G12C Mutation, Unresectable Colorectal Cancer","enrollment":300},{"nctId":"NCT03740893","phase":"PHASE2","title":"PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"Institute of Cancer Research, United Kingdom","startDate":"2019-10-15","conditions":"Breast Neoplasm, Triple Negative Breast Cancer (TNBC), HRD","enrollment":119},{"nctId":"NCT03793478","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2018-08-15","conditions":"Acute Myeloid Leukemia","enrollment":65},{"nctId":"NCT06262438","phase":"PHASE2","title":"CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients","status":"RECRUITING","sponsor":"Princess Maxima Center for Pediatric Oncology","startDate":"2024-02-06","conditions":"Acute Myeloid Leukemia in Children","enrollment":60},{"nctId":"NCT02276443","phase":"NA","title":"Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-11-09","conditions":"Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7","enrollment":798},{"nctId":"NCT06876636","phase":"NA","title":"Zoledronic Acid Combined With EC-T for Triple-Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Xijing Hospital","startDate":"2025-03-10","conditions":"Breast Cancer Metastatic","enrollment":99},{"nctId":"NCT03654547","phase":"PHASE1","title":"Safety of TT-00420 (Tinengotinib) Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer","status":"COMPLETED","sponsor":"TransThera Sciences (Nanjing), Inc.","startDate":"2019-01-08","conditions":"Advanced Solid Tumors, Triple Negative Breast Cancer","enrollment":48},{"nctId":"NCT02908672","phase":"PHASE3","title":"A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-01-13","conditions":"Melanoma","enrollment":514},{"nctId":"NCT07020052","phase":"","title":"Phase II Exploratory Study of Sequential Triple Therapy (Temozolomide/Anlotinib/Bemarituzumab) in Combination With Concurrent Radiotherapy With Temozolomide and Anlotinib for the Maintenance Treatment of Diffuse Midline Gliomas in Children","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2025-07-10","conditions":"Maintenance Treatment of Diffuse Midline Gliomas in Children","enrollment":33},{"nctId":"NCT07032714","phase":"PHASE1","title":"Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2025-12-16","conditions":"Relapsed Refractory Multiple Myeloma (RRMM)","enrollment":25},{"nctId":"NCT06819319","phase":"PHASE2","title":"SHR-A2102 Combined With Adebrelimab as Neoadjuvant Therapy for Early Triple-Negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2025-06-23","conditions":"TNBC - Triple-Negative Breast Cancer","enrollment":52},{"nctId":"NCT05253495","phase":"PHASE2","title":"Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma","status":"RECRUITING","sponsor":"New York Medical College","startDate":"2022-02-01","conditions":"Non-hodgkin Lymphoma, Hodgkin Lymphoma","enrollment":80},{"nctId":"NCT06067061","phase":"PHASE1, PHASE2","title":"\"neoBREASTIM\": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer","status":"TERMINATED","sponsor":"Institut Curie","startDate":"2024-04-05","conditions":"Triple Negative Breast Neoplasms","enrollment":2},{"nctId":"NCT05253846","phase":"PHASE2","title":"Short-course Radiotherapy Followed by Consolidation Chemotherapy. 2021-001206-29","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2022-01-25","conditions":"Locally Advanced Rectal Cancer","enrollment":63},{"nctId":"NCT07010393","phase":"PHASE4","title":"Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study","status":"NOT_YET_RECRUITING","sponsor":"Fujian Medical University","startDate":"2025-07-01","conditions":"Thyroid Neoplasms","enrollment":335},{"nctId":"NCT07005583","phase":"PHASE2","title":"Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent or Metastatic Triple-Negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-06-30","conditions":"Triple-Negative Breast Cancer (TNBC)","enrollment":46},{"nctId":"NCT07000344","phase":"NA","title":"A Study of Apatinib Combined With Letrozole With or Without Fluzoparib in Estrogen Receptor-Positive, Platinum-Sensitive Recurrent Ovarian Cancer Previously Treated With First-Line PARP Inhibitor","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-07-01","conditions":"Ovarian Cancer","enrollment":70},{"nctId":"NCT06992336","phase":"PHASE2","title":"Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-04-10","conditions":"Breast Cancer","enrollment":411},{"nctId":"NCT06033131","phase":"PHASE3","title":"PI4 - A Trial Assessing Metformin to Prolong Gestation in Preterm Preeclampsia","status":"RECRUITING","sponsor":"Lina Bergman","startDate":"2024-01-19","conditions":"Preeclampsia","enrollment":294},{"nctId":"NCT06426108","phase":"PHASE4","title":"Interventions to Control Hypersensitivity Pain in Teeth With Insisive Molar Hypomineralization","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2024-07-01","conditions":"Molar Incisor Hypomineralization","enrollment":72},{"nctId":"NCT06000462","phase":"PHASE4","title":"The Effect of Dapagliflozin on Weight Loss in Obese Adults Without Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Oman Ministry of Health","startDate":"2024-04-22","conditions":"Obesity, Dapagliflozin Adverse Reaction, Weight Loss","enrollment":150},{"nctId":"NCT06105775","phase":"NA","title":"Inorganic Nitrate Supplementation in Chronic Hypertensive Pregnancies","status":"RECRUITING","sponsor":"University of Sao Paulo","startDate":"2025-03-06","conditions":"Hypertension in Pregnancy, Hypertension, Pregnancy","enrollment":144},{"nctId":"NCT04494958","phase":"PHASE1, PHASE2","title":"Palbociclib and Binimetinib in Advanced Triple Negative Breast Cancer","status":"COMPLETED","sponsor":"Fundacion Oncosur","startDate":"2020-11-18","conditions":"Triple Negative Breast Cancer","enrollment":24},{"nctId":"NCT06863532","phase":"NA","title":"Efficacy and Safety Comparison of Cofrogliptin Add-on Versus Metformin Dose-escalation in Type 2 Diabetes Patients Inadequately Controlled With SGLT-2 Inhibitors Plus Low-Dose Metformin:A Multicenter, Open-Label Trial","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-03-30","conditions":"Type 2 Diabetes","enrollment":80},{"nctId":"NCT06425666","phase":"NA","title":"Trial Comparing Cataract Surgery With Triple-DMEK in Patients With Cataract and Fuchs Endothelial Corneal Dystrophy","status":"RECRUITING","sponsor":"University of Cologne","startDate":"2025-01-24","conditions":"Cataract Surgery, Cataract and Fuchs Endothelial Corneal Dystrophy","enrollment":120},{"nctId":"NCT06338826","phase":"PHASE2","title":"Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses","status":"NOT_YET_RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2025-02-01","conditions":"HIV Infections, HBV Coinfection","enrollment":140},{"nctId":"NCT04599634","phase":"PHASE1","title":"Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-12-16","conditions":"Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma","enrollment":11},{"nctId":"NCT05539365","phase":"PHASE2","title":"Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer","status":"WITHDRAWN","sponsor":"Roswell Park Cancer Institute","startDate":"2025-02-01","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma","enrollment":""},{"nctId":"NCT06709963","phase":"NA","title":"The Effect of Intermittent Theta Burst Stimulation on Brain Characteristics, Pain Intensity, and Cognitive Functions in Older People with Chronic Musculoskeletal Pain.","status":"RECRUITING","sponsor":"The Hong Kong Polytechnic University","startDate":"2024-09-20","conditions":"Chronic Non-Specific Low Back Pain, Chronic Knee Pain, Chronic Musculoskeletal Pain","enrollment":30},{"nctId":"NCT06737913","phase":"PHASE2","title":"HAI or IV of Adebrelimab, Combined with Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-12","conditions":"Advanced Hepatocellular Carcinoma (HCC)","enrollment":78},{"nctId":"NCT06636981","phase":"PHASE2","title":"All Trans Retinoic Acid Combined with Toripalimab+Chemotherapy for Locally Advanced Inoperable or Metastatic Triple Negative Breast Cancer：a Multi-center, Multi-cohort Phase II Trial","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-11-04","conditions":"Triple Negative Breast Cancer (TNBC)","enrollment":129},{"nctId":"NCT06401005","phase":"PHASE2","title":"SBRT, Chemotherapy, and AK104 Neoadjuvant Therapy for Triple-negative Breast Cancer (TNBC)","status":"RECRUITING","sponsor":"Hubei Cancer Hospital","startDate":"2024-11-28","conditions":"Breast Cancer","enrollment":51},{"nctId":"NCT03761914","phase":"PHASE1, PHASE2","title":"Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers","status":"COMPLETED","sponsor":"Sellas Life Sciences Group","startDate":"2019-09-30","conditions":"Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer","enrollment":26},{"nctId":"NCT03800836","phase":"PHASE1","title":"A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-02-13","conditions":"Breast Cancer","enrollment":139}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":606,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Continue with triple therapy","genericName":"Continue with triple therapy","companyName":"Hospitales Universitarios Virgen del Rocío","companyId":"hospitales-universitarios-virgen-del-roc-o","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}